COVID-19 plasma therapy, backed by Mayo research, will reach more patients


August 25, 2020

Mayo Clinic announced Monday that it has discontinued its COVID-19 plasma therapy study now that the FDA has approved emergency use of plasma therapy.

More COVID-19 patients are expected to receive convalescent plasma therapy since the Trump administration issued an emergency authorization Sunday, backed by research from the Mayo Clinic in Rochester.

"This makes it simpler for hospitals to get access to convalescent plasma," said Dr. R. Scott Wright, a coordinator of Mayo's national plasma program.

The treatment involves a transfusion of blood plasma from someone who has recovered from the new coronavirus into a newly infected patient with the hope that the antibodies in the plasma will prevent complications and speed recovery.


Reader Comments(0)


Powered by ROAR Online Publication Software from Lions Light Corporation
© Copyright 2020